The abuse potential of the synthetic cannabinoid nabilone.
about
Medical marijuana: medical necessity versus political agendaGastroparesis: concepts, controversies, and challengesUsing Social Listening Data to Monitor Misuse and Nonmedical Use of Bupropion: A Content Analysis.The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for painUse of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation.Blurred boundaries: the therapeutics and politics of medical marijuana.[Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline].Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial.Prescribing smoked cannabis for chronic noncancer pain: preliminary recommendationsTreating pain in multiple sclerosis.Separate and combined effects of the cannabinoid agonists nabilone and Δ⁹-THC in humans discriminating Δ⁹-THCSubjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers.Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis.Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapseEffects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis usersReview of pharmacological therapies in fibromyalgia syndrome.Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine.Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial.Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia.Using cannabinoids in pain and palliative care.Cannabis and Cannabinoids for Chronic Pain.Update on Treatment Guideline in Fibromyalgia Syndrome with Focus on Pharmacology.Addictive potential of novel treatments for refractory depression and anxiety.
P2860
Q24633493-29B52D03-7C8A-4B7F-B2D0-BD451C7C81BCQ26998965-B1C29A4D-3395-45D3-9AEC-A5DD2C0C9EDBQ31158757-B7C3CB2A-285C-4D75-BBF8-242132D36A09Q33578856-01F905F9-82A2-4659-85A6-25763416AA9AQ34194009-4A214DF2-BBBB-4566-B32E-610FE0D97A37Q34251969-94C599A9-1DAC-4223-AA46-0B38A5E16CD3Q34285830-8E0155FA-24E4-445B-9B70-31FA5CC38DA5Q34306281-9C967FBC-1585-4429-AA76-853BE20EA7F9Q34453438-6F4B1B32-BDD2-4026-9168-B821DD252913Q34632301-D18BAEBB-C064-406D-974F-868AE29E7BE9Q34950909-25BF3211-5A93-467A-A730-429039823F1CQ35911283-6AEBC187-18C7-4F25-9C75-F4A42B0FB8EBQ36157623-0A5A0530-4C22-49DB-82A3-72D4EC9CDE67Q36927776-D1CD2D1F-358E-431A-A3A3-947BAA5AC657Q37635636-FF20EDDF-5BBE-48AD-A704-4079CC867082Q37691161-A37DB9B6-C38A-4582-B559-D0321A5FB41AQ37871980-12412827-2853-48B4-AF08-A4341FFCC168Q39200153-D413FC82-207D-490A-A931-5C1D902B36A6Q39245884-A462F39D-FDD2-42D9-8707-B38D6D9CEC1EQ39278073-A21CC51F-F648-4E8E-B364-938CA419D7E7Q43075872-F48826AA-C6CC-4BA2-8B18-E3BC2C762317Q51817192-9170866E-CE67-45FC-A580-0FC371A55AE2Q55334438-43FAD1A0-59D7-48A6-ABD1-9C15A794A89C
P2860
The abuse potential of the synthetic cannabinoid nabilone.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The abuse potential of the synthetic cannabinoid nabilone.
@en
The abuse potential of the synthetic cannabinoid nabilone.
@nl
type
label
The abuse potential of the synthetic cannabinoid nabilone.
@en
The abuse potential of the synthetic cannabinoid nabilone.
@nl
prefLabel
The abuse potential of the synthetic cannabinoid nabilone.
@en
The abuse potential of the synthetic cannabinoid nabilone.
@nl
P2860
P1433
P1476
The abuse potential of the synthetic cannabinoid nabilone.
@en
P2093
Emmanuelle St Arnaud-Trempe
Mark A Ware
P2860
P304
P356
10.1111/J.1360-0443.2009.02776.X
P407
P577
2010-03-01T00:00:00Z